The Non-Insulin Diabetes Therapeutics Market is expected to grow at a CAGR of 12.17% to reach USD 39722.1 million by 2028. In the Non-Insulin Diabetes Therapeutics Market, advanced treatments for diabetes are being introduced by various vendors. Notably, incretin hormones, specifically GLP-1 and GIP, secreted by the GI tract in response to food consumption, play a significant role in insulin secretion. These hormones stimulate the beta cells of the pancreas, contributing to approximately 60% of insulin production post-meal. Type 2 diabetes patients experience reduced GLP-1 secretion and responsiveness to GIP, leading to impaired glycemic control. Incretin hormones offer several benefits, including enhanced satiety, decreased gastrointestinal motility, increased insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release. Two classes of incretin-based drugs, GLP-1 receptor agonists and DPP-4 inhibitors, are utilized to manage type 2 diabetes effectively.
North America dominates the regional market because of The Non-Insulin Diabetes Therapeutics market represents a significant business opportunity, driven by the increasing prevalence of diabetes and the growing demand for alternative treatment options. Key players in this market include Merck & Co., Sanofi, Novo Nordisk, and Eli Lilly and Company. These companies offer a range of non-insulin diabetes therapies, such as GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors, to manage blood sugar levels effectively and improve patient outcomes. The market is expected to grow steadily due to the expanding patient population and the continuous development of innovative therapeutic solutions.
There are various factors that drive the Non-Insulin Diabetes Therapeutics Market market which are as following: Type 2 diabetes is a metabolic disorder characterized by hyperglycemia and insulin resistance or deficiency. This condition arises when the body fails to effectively utilize insulin, leading to an accumulation of glucose in the bloodstream. Prevalent causes include excess body weight and physical inactivity. Once diagnosed, timely administration of advanced non-insulin therapeutics becomes crucial due to the generic and often overlooked symptoms of the disease. The prevalence of type 2 diabetes among children has been on the rise, making early and accurate diagnosis and treatment increasingly important. Non-insulin diabetes therapeutics target various aspects of glucose metabolism to effectively manage blood sugar levels and mitigate the complications associated with this chronic condition.
Be the first one to get the industry updates. Request for a sample report
Non-Insulin Diabetes Therapeutics Market Segmentation
The market witnesses several challenges, which are as follows The US Food and Drug Administration (FDA) is currently assessing several non-insulin diabetes therapeutics due to safety concerns. In 2017, the FDA issued a boxed warning for Janssen Pharmaceuticals' type 2 diabetes therapeutics, including Invokana, Invokamet, and Invokamet XR, due to an increased risk of leg and foot amputations. Consequently, these medications must carry a description of the risk in a prominent box near the label of their canagliflozin drugs. Additionally, in 2015, the FDA revised the labels of SGLT2 inhibitors to include warnings about the potential risks of metabolic acidosis and severe urinary tract infections (UTIs). These developments underscore the importance of ongoing regulatory scrutiny and transparency in the non-insulin diabetes therapeutics market.
Stay ahead of your competitors. Download the Free PDF report
Some of the key companies that have been profiled in the report include:
Market Research Overview
The Non-Insulin Diabetes Therapeutics market is a significant segment of the larger global pharmaceuticals industry, encompassing companies involved in the research and development (R&D) or production of both generic and non-generic drugs. According to Technavio's market analysis, the healthcare sector's total revenue is determined by the combined earnings of manufacturers and providers in the equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services sectors. Factors driving the growth of the pharmaceuticals market include the increasing global population aging, with Europe and the US projected to have over 25% of their populations aged 60 years or above by 2030 and 2050, respectively. - The Non-Insulin Diabetes Therapeutics Market is experiencing significant growth, fueled by the Increasing number of people with type 2 diabetes. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
The Non-Insulin Diabetes Therapeutics Market is witnessing significant growth due to increasing patient awareness and innovative therapies. The market includes various drug classes such as DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and metformin. The route of administration varies from oral to injectable, with the dominance of hospital pharmacies for insulin therapy and e-commerce platforms for oral medications. Glycemic control remains the primary focus of diabetes treatment, leading to therapeutic innovations like continuous glucose monitoring and biosimilar insulins. FDA approvals for new drugs and strategic alliances between pharmaceutical companies are driving market growth. Diabetes Type 1 and Type 2 patients utilize both retail and hospital pharmacies for their medication needs. Insulin remains a crucial component of diabetes treatment, with combination drugs gaining popularity. Incretins, a newer class of drugs, are also making an impact in diabetes management. Diabetes devices, such as insulin pumps and continuous glucose monitoring systems, are revolutionizing diabetes care. The market is expected to witness further growth with the introduction of new therapeutic options and technological advancements. In summary, the Non-Insulin Diabetes Therapeutics Market is a dynamic and evolving industry driven by patient awareness, therapeutic innovation, and strategic partnerships. The market includes various drug classes, administration routes, and distribution channels, catering to the diverse needs of diabetes patients.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
